Cargando…

Treatment of Peritoneal Surface Malignancies by Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Spain: Results of the National Registry of the Spanish Group of Peritoneal Oncologic Surgery (REGECOP)

Introduction: Treatment of Peritoneal Surface Malignancies (PSM) with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has achieved results never seen before in these patients, which classically have a poor prognosis. The possibility of conducting clinical trials in...

Descripción completa

Detalles Bibliográficos
Autores principales: Manzanedo, Israel, Pereira, Fernando, Cascales-Campos, Pedro, Muñoz-Casares, Cristobal, Asensio, Enrique, Torres-Melero, Juan, Prada-Villaverde, Arancha, Caravaca-García, Ibán, Gutiérrez-Calvo, Alberto, Vaqué, Javier, Ortega, Gloria, Titos-García, Alberto, González-Sánchez, Laura, Pérez-Viejo, Estíbalitz, Serrano, Ángel, Martínez-Torres, Beatriz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10253421/
https://www.ncbi.nlm.nih.gov/pubmed/37297969
http://dx.doi.org/10.3390/jcm12113774
_version_ 1785056401909874688
author Manzanedo, Israel
Pereira, Fernando
Cascales-Campos, Pedro
Muñoz-Casares, Cristobal
Asensio, Enrique
Torres-Melero, Juan
Prada-Villaverde, Arancha
Caravaca-García, Ibán
Gutiérrez-Calvo, Alberto
Vaqué, Javier
Ortega, Gloria
Titos-García, Alberto
González-Sánchez, Laura
Pérez-Viejo, Estíbalitz
Serrano, Ángel
Martínez-Torres, Beatriz
author_facet Manzanedo, Israel
Pereira, Fernando
Cascales-Campos, Pedro
Muñoz-Casares, Cristobal
Asensio, Enrique
Torres-Melero, Juan
Prada-Villaverde, Arancha
Caravaca-García, Ibán
Gutiérrez-Calvo, Alberto
Vaqué, Javier
Ortega, Gloria
Titos-García, Alberto
González-Sánchez, Laura
Pérez-Viejo, Estíbalitz
Serrano, Ángel
Martínez-Torres, Beatriz
author_sort Manzanedo, Israel
collection PubMed
description Introduction: Treatment of Peritoneal Surface Malignancies (PSM) with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has achieved results never seen before in these patients, which classically have a poor prognosis. The possibility of conducting clinical trials in these diseases is complicated, since some of them are rare, so the analysis of large databases provides very valuable scientific information. The aim of this study is to analyze the global results of the National Registry of the Spanish Group of Peritoneal Oncologic Surgery (REGECOP), whose objective is to register all patients scheduled for HIPEC nationwide. Methods: This is a retrospective analysis of the data recorded in the REGECOP from 36 Spanish hospitals from 2001 to 2021. There were 4159 surgical interventions in 3980 patients. Results: 66% are women and 34% are men with a median age of 59 years (range 17–86). 41.5% of the patients were treated for Peritoneal Metastases (PM) of colorectal cancer (CRC); 32.4% were women with ovarian cancer (OC) with PM; 12.8% were treated for pseudomyxoma peritonei (PMP); 6.2% had PM from gastric cancer (GC); 4.9% had PM of non-conventional origin; and, finally, 2.1% of cases were patients diagnosed with peritoneal mesothelioma. The median Peritoneal Cancer Index (PCI) was 9 (0–39), and complete cytoreduction was achieved in 81.7% of the procedures. Severe morbidity (Dindo–Clavien grade III–IV) was observed in 17.7% of surgeries, with 2.1% mortality. Median hospital stay was 11 days (0–259). Median overall survival (OS) was 41 months for CRC patients, 55 months for women with OC, was not reached in PMP patients, was 14 months for GC patients, and 66 months in mesothelioma patients. Conclusions: large databases provide extremely useful data. CRS with HIPEC in referral centers is a safe treatment with encouraging oncologic results in PSM.
format Online
Article
Text
id pubmed-10253421
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102534212023-06-10 Treatment of Peritoneal Surface Malignancies by Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Spain: Results of the National Registry of the Spanish Group of Peritoneal Oncologic Surgery (REGECOP) Manzanedo, Israel Pereira, Fernando Cascales-Campos, Pedro Muñoz-Casares, Cristobal Asensio, Enrique Torres-Melero, Juan Prada-Villaverde, Arancha Caravaca-García, Ibán Gutiérrez-Calvo, Alberto Vaqué, Javier Ortega, Gloria Titos-García, Alberto González-Sánchez, Laura Pérez-Viejo, Estíbalitz Serrano, Ángel Martínez-Torres, Beatriz J Clin Med Article Introduction: Treatment of Peritoneal Surface Malignancies (PSM) with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has achieved results never seen before in these patients, which classically have a poor prognosis. The possibility of conducting clinical trials in these diseases is complicated, since some of them are rare, so the analysis of large databases provides very valuable scientific information. The aim of this study is to analyze the global results of the National Registry of the Spanish Group of Peritoneal Oncologic Surgery (REGECOP), whose objective is to register all patients scheduled for HIPEC nationwide. Methods: This is a retrospective analysis of the data recorded in the REGECOP from 36 Spanish hospitals from 2001 to 2021. There were 4159 surgical interventions in 3980 patients. Results: 66% are women and 34% are men with a median age of 59 years (range 17–86). 41.5% of the patients were treated for Peritoneal Metastases (PM) of colorectal cancer (CRC); 32.4% were women with ovarian cancer (OC) with PM; 12.8% were treated for pseudomyxoma peritonei (PMP); 6.2% had PM from gastric cancer (GC); 4.9% had PM of non-conventional origin; and, finally, 2.1% of cases were patients diagnosed with peritoneal mesothelioma. The median Peritoneal Cancer Index (PCI) was 9 (0–39), and complete cytoreduction was achieved in 81.7% of the procedures. Severe morbidity (Dindo–Clavien grade III–IV) was observed in 17.7% of surgeries, with 2.1% mortality. Median hospital stay was 11 days (0–259). Median overall survival (OS) was 41 months for CRC patients, 55 months for women with OC, was not reached in PMP patients, was 14 months for GC patients, and 66 months in mesothelioma patients. Conclusions: large databases provide extremely useful data. CRS with HIPEC in referral centers is a safe treatment with encouraging oncologic results in PSM. MDPI 2023-05-31 /pmc/articles/PMC10253421/ /pubmed/37297969 http://dx.doi.org/10.3390/jcm12113774 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Manzanedo, Israel
Pereira, Fernando
Cascales-Campos, Pedro
Muñoz-Casares, Cristobal
Asensio, Enrique
Torres-Melero, Juan
Prada-Villaverde, Arancha
Caravaca-García, Ibán
Gutiérrez-Calvo, Alberto
Vaqué, Javier
Ortega, Gloria
Titos-García, Alberto
González-Sánchez, Laura
Pérez-Viejo, Estíbalitz
Serrano, Ángel
Martínez-Torres, Beatriz
Treatment of Peritoneal Surface Malignancies by Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Spain: Results of the National Registry of the Spanish Group of Peritoneal Oncologic Surgery (REGECOP)
title Treatment of Peritoneal Surface Malignancies by Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Spain: Results of the National Registry of the Spanish Group of Peritoneal Oncologic Surgery (REGECOP)
title_full Treatment of Peritoneal Surface Malignancies by Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Spain: Results of the National Registry of the Spanish Group of Peritoneal Oncologic Surgery (REGECOP)
title_fullStr Treatment of Peritoneal Surface Malignancies by Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Spain: Results of the National Registry of the Spanish Group of Peritoneal Oncologic Surgery (REGECOP)
title_full_unstemmed Treatment of Peritoneal Surface Malignancies by Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Spain: Results of the National Registry of the Spanish Group of Peritoneal Oncologic Surgery (REGECOP)
title_short Treatment of Peritoneal Surface Malignancies by Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Spain: Results of the National Registry of the Spanish Group of Peritoneal Oncologic Surgery (REGECOP)
title_sort treatment of peritoneal surface malignancies by cytoreductive surgery (crs) and hyperthermic intraperitoneal chemotherapy (hipec) in spain: results of the national registry of the spanish group of peritoneal oncologic surgery (regecop)
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10253421/
https://www.ncbi.nlm.nih.gov/pubmed/37297969
http://dx.doi.org/10.3390/jcm12113774
work_keys_str_mv AT manzanedoisrael treatmentofperitonealsurfacemalignanciesbycytoreductivesurgerycrsandhyperthermicintraperitonealchemotherapyhipecinspainresultsofthenationalregistryofthespanishgroupofperitonealoncologicsurgeryregecop
AT pereirafernando treatmentofperitonealsurfacemalignanciesbycytoreductivesurgerycrsandhyperthermicintraperitonealchemotherapyhipecinspainresultsofthenationalregistryofthespanishgroupofperitonealoncologicsurgeryregecop
AT cascalescampospedro treatmentofperitonealsurfacemalignanciesbycytoreductivesurgerycrsandhyperthermicintraperitonealchemotherapyhipecinspainresultsofthenationalregistryofthespanishgroupofperitonealoncologicsurgeryregecop
AT munozcasarescristobal treatmentofperitonealsurfacemalignanciesbycytoreductivesurgerycrsandhyperthermicintraperitonealchemotherapyhipecinspainresultsofthenationalregistryofthespanishgroupofperitonealoncologicsurgeryregecop
AT asensioenrique treatmentofperitonealsurfacemalignanciesbycytoreductivesurgerycrsandhyperthermicintraperitonealchemotherapyhipecinspainresultsofthenationalregistryofthespanishgroupofperitonealoncologicsurgeryregecop
AT torresmelerojuan treatmentofperitonealsurfacemalignanciesbycytoreductivesurgerycrsandhyperthermicintraperitonealchemotherapyhipecinspainresultsofthenationalregistryofthespanishgroupofperitonealoncologicsurgeryregecop
AT pradavillaverdearancha treatmentofperitonealsurfacemalignanciesbycytoreductivesurgerycrsandhyperthermicintraperitonealchemotherapyhipecinspainresultsofthenationalregistryofthespanishgroupofperitonealoncologicsurgeryregecop
AT caravacagarciaiban treatmentofperitonealsurfacemalignanciesbycytoreductivesurgerycrsandhyperthermicintraperitonealchemotherapyhipecinspainresultsofthenationalregistryofthespanishgroupofperitonealoncologicsurgeryregecop
AT gutierrezcalvoalberto treatmentofperitonealsurfacemalignanciesbycytoreductivesurgerycrsandhyperthermicintraperitonealchemotherapyhipecinspainresultsofthenationalregistryofthespanishgroupofperitonealoncologicsurgeryregecop
AT vaquejavier treatmentofperitonealsurfacemalignanciesbycytoreductivesurgerycrsandhyperthermicintraperitonealchemotherapyhipecinspainresultsofthenationalregistryofthespanishgroupofperitonealoncologicsurgeryregecop
AT ortegagloria treatmentofperitonealsurfacemalignanciesbycytoreductivesurgerycrsandhyperthermicintraperitonealchemotherapyhipecinspainresultsofthenationalregistryofthespanishgroupofperitonealoncologicsurgeryregecop
AT titosgarciaalberto treatmentofperitonealsurfacemalignanciesbycytoreductivesurgerycrsandhyperthermicintraperitonealchemotherapyhipecinspainresultsofthenationalregistryofthespanishgroupofperitonealoncologicsurgeryregecop
AT gonzalezsanchezlaura treatmentofperitonealsurfacemalignanciesbycytoreductivesurgerycrsandhyperthermicintraperitonealchemotherapyhipecinspainresultsofthenationalregistryofthespanishgroupofperitonealoncologicsurgeryregecop
AT perezviejoestibalitz treatmentofperitonealsurfacemalignanciesbycytoreductivesurgerycrsandhyperthermicintraperitonealchemotherapyhipecinspainresultsofthenationalregistryofthespanishgroupofperitonealoncologicsurgeryregecop
AT serranoangel treatmentofperitonealsurfacemalignanciesbycytoreductivesurgerycrsandhyperthermicintraperitonealchemotherapyhipecinspainresultsofthenationalregistryofthespanishgroupofperitonealoncologicsurgeryregecop
AT martineztorresbeatriz treatmentofperitonealsurfacemalignanciesbycytoreductivesurgerycrsandhyperthermicintraperitonealchemotherapyhipecinspainresultsofthenationalregistryofthespanishgroupofperitonealoncologicsurgeryregecop
AT treatmentofperitonealsurfacemalignanciesbycytoreductivesurgerycrsandhyperthermicintraperitonealchemotherapyhipecinspainresultsofthenationalregistryofthespanishgroupofperitonealoncologicsurgeryregecop